Targeting STAT3, FOXO3a, and Pim‐1 kinase by FDA‐approved tyrosine kinase inhibitor–Radotinib: An in silico and in vitro approach
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Suryaa Manoharan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Toxicology Laboratory, Department of Biotechnology, Bharathiar University, Coimbatore, India. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Forkhead Box Protein O3, Proto-Oncogene Proteins c-pim-1, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 102 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Indian Council of Medical Research, CSIR Direct-SRF.
Abstract (Originalsprache)
Cancer, a multifactorial pathological condition, is primarily caused due to mutations in multiple genes. Hepatocellular carcinoma (HCC) is a form of primary liver cancer that is often diagnosed at the advanced stage. Current treatment strategies for advanced HCC involve systemic therapies which are often hindered due to the emergence of resistance and toxicity. Therefore, a multitarget approach might prove more effective in HCC treatment. The present study focuses on targeting signal transducer and activator of transcription 3 (STAT3), forkhead box class O3a (FOXO3a), and proviral integration site for Moloney murine leukemia virus‐1 (Pim‐1) kinase, using a Food and Drug Administration (FDA)‐approved anticancer drug library. Two compounds, namely, radotinib and capmatinib, were identified as top compounds using molecular docking. Among the two compounds, radotinib exhibited significant binding values towards the targeted proteins and their heterodimers. Furthermore, in vitro experiments involving 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium bromide (MTT), live/dead, 4′,6‐diamidino‐2‐phenylindole, and clonogenic assays were performed to evaluate the effect of radotinib in human hepatoblastoma cell line/hepatocellular carcinoma cells. The gene expression data indicated reduced expression of FOXO3a and Pim‐1, but no basal‐level alteration of STAT3. The Western blot analysis assay showed that the phosphorylation level of STAT3 was significantly decreased upon radotinib treatment. Taken together, our findings suggest that radotinib, which is currently used in the treatment of chronic myeloid leukemia (CML), could be considered as a potential candidate for repurposing in the treatment of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Toxicology Laboratory, Department of Biotechnology, Bharathiar University, Coimbatore, India.
ORCID-Profile: Suryaa Manoharan
Förderung
- Council of Scientific and Industrial Research, India
- Indian Council of Medical Research
- CSIR Direct-SRF
- ICMR
Zitieren
APA
Manoharan, S., Santhakumar, A., & Perumal, E. (2024). Targeting STAT3, FOXO3a, and Pim‐1 kinase by FDA‐approved tyrosine kinase inhibitor–Radotinib: An in silico and in vitro approach. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400429
Vancouver
Manoharan S, Santhakumar A, Perumal E. Targeting STAT3, FOXO3a, and Pim‐1 kinase by FDA‐approved tyrosine kinase inhibitor–Radotinib: An in silico and in vitro approach. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400429
BibTeX
@article{Manoharan2024,
author = {Manoharan, Suryaa and Santhakumar, Aksayakeerthana and Perumal, Ekambaram},
title = {Targeting STAT3, FOXO3a, and Pim‐1 kinase by FDA‐approved tyrosine kinase inhibitor–Radotinib: An in silico and in vitro approach},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400429}
}
EUVIMED